A developed model of cancer patients participation in intravenous chemotherapy safety

// Zeng Na 1 , Yan Qiaoyuan 2 , Wang Binghan 2 , Zhu Qin 3 , Chen Yue 4 , Peng Xin 2 , Tan Cuilian 2 and Yao Cheng 5 1 College of Medical Science, China Three Gorges University, Yichang 443000, Hubei, China 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China 3 School of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China 4 First Affiliated Hospital, Chongqing Medical University, Yuzhong 400000, Chongqing, China 5 Public Health Department, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China Correspondence to: Yan Qiaoyuan, email: yanqiaoyuan@163.com Keywords: patient participation, safety, model, intravenous chemotherapy, cancer Received: July 15, 2017 Accepted: August 27, 2017 Published: September 18, 2017 ABSTRACT How to reduce intravenous chemotherapy-related adverse reactions of cancer patients is one focus of clinical work. Nowadays, patient for patient safety (PFPS) is an important component of hospital safety management and can contribute to a reduction in the rate of adverse events following intravenous chemotherapy of cancer patients. To guide and evaluate cancer patients participate in intravenous chemotherapy, we explored a scientific and practical model of cancer patients participation in intravenous chemotherapy safety. which can also guide nurse practitioners (NPs) practice. Based on a literature review and analysis of chemotherapy-associated adverse events from two large comprehensive hospitals, combined with the existing strategies for PFPS, the model of cancer patients participation in intravenous chemotherapy safety was drafted. Then we conducted two rounds of the Delphi-method questionnaire to revise the model. The two rounds Delphi questionnaire survey had a response rate of 82.36%. The authoritative coefficient was 0.87 and the coordination coefficients were 0.165 and 0.214, respectively. The proposed safety model included 3 first-order indicators, 8 second-order indicators, and 41 third-order indicators, including content of patients participation, responsibilities of medical personnel to assist cancer patients participation, and suggestions for guaranteeing implementation. Many NPs practice in a medical setting where cancer patients for patient safety behavior are blurred. The model of cancer patients participation in intravenous chemotherapy safety can guide NPs in their practice of promoting PFPS among cancer patients intravenous chemotherapy.